WELCOME TO THE MINDMATTERS ASCO EDITION
In 2019, it is estimated that 86,970 new cases of primary malignant and non-malignant brain and other central nervous system tumors will be diagnosed in the United States.
BRAIN TUMOR RESEARCH NEWS FROM 2019 AMERICAN SOCIETY FOR CLINICAL ONCOLOGY MEETING
The ABTA team met with constituents and attended a variety of brain tumor research sessions at the American Society of Clinical Oncology (ASCO) Annual Meeting. While the ABTA team couldn’t attend all of the research sessions, a couple of themes emerged. Read on for the full reporting from ASCO.
MOVING BEYOND TUMOR TYPE TO TUMOR AGNOSTIC TREATMENT
Until recently, drug discovery has traditionally focused on the development of a therapy to treat a specific tumor type based on the origin of the cancer. While the drug development process continues to reflect this approach, the emergence of new insights into the biology of cancer cells has revealed cancer cells have molecular characteristics that are not unique to the origin of the cancer.
THE IMPORTANCE OF BRAIN TUMOR TISSUE TESTING
With the molecular make-up of cancer cells emerging as a new pathway to combat cancer, tumor tissue testing will become critical to determining effective treatment approaches.
LAROTRECTINIB CONTINUES TO SHOW PROMISE IN TREATING BRAIN CANCER
Larotrectinib, a targeted therapy, continues to show promise in treating patients with brain cancer in the latest clinical research.
SURVAXM WITH STANDARD THERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA: PHASE II TRIAL UPDATE
SurVaxM is a cancer immunotherapy vaccine (boosts body’s own immune system to fight cancer cells) designed to target and attack cancer cells with survivin (an antigen produced in cancer cells).
BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS
A major impediment to improving brain tumor outcomes is poor clinical trial accrual. In fact, only 20 percent of neuro-oncology patients enroll in clinical trials.
90 PERCENT OF CANCER PATIENTS AND CAREGIVERS SURPRISED AT METASTATIC BRAIN TUMOR DIAGNOSIS
The American Brain Tumor Association presented preliminary survey findings from the first phase of the ABTA Metastatic Brain Tumor Initiative at the American Society Clinical Oncology Annual Meeting.
Upcoming Events
 |
|
|
| October 12, 2019 BT5K Run & Walk Twin Cities St. Paul, MN |
October 26, 2019 BT5K Run & Walk Los Angeles Los Angeles, CA |
October 27, 2019 BT5K Run & Walk San Francisco San Francisco, CA |
| LEARN MORE | LEARN MORE | LEARN MORE |
About Meet Hope Head On
Because of the generous support from people like you, the ABTA has given over $35 million for brain tumor research. The ABTA’s campaign, “Meet Hope Head On,” created for our 50th anniversary, is focused on raising $50 million, in part to fund critical brain tumor research. This campaign is vital for continuing the kind of work that led to the recent FDA approval of vorasidenib, a breakthrough treatment for low-grade glioma.
